This review provides an update on the current clinical and preclinical understanding of chemotherapy induced peripheral neuropathy (CIPN). The overview of the clinical syndrome includes a review of its assessment, diagnosis and treatment. CIPN is caused by several widely-used chemotherapeutics including paclitaxel, oxaliplatin, bortezomib. Severe CIPN may require dose reduction, or cessation, of chemotherapy, impacting on patient survival. While CIPN often resolves after chemotherapy, around 30% of patients will have persistent problems, impacting on function and quality of life. Early assessment and diagnosis is important, and we discuss tools developed for this purpose. There are no effective strategies to prevent CIPN, with limited evidence of effective drugs for treating established CIPN. Duloxetine has moderate evidence, with extrapolation from other neuropathic pain states generally being used to direct treatment options for CIPN. The preclinical perspective includes a discussion on the development of clinically-relevant rodent models of CIPN and some of the potentially modifiable mechanisms that have been identified using these models. We focus on the role of mitochondrial dysfunction, oxidative stress, immune cells and changes in ion channels from summary of the latest literature in these areas. Many causal mechanisms of CIPN occur simultaneously and/or can reinforce each other. Thus, combination therapies may well be required for most effective management. More effective treatment of CIPN will require closer links between oncology and pain management clinical teams to ensure CIPN patients are effectively monitored. Furthermore, continued close collaboration between clinical and preclinical research will facilitate the development of novel treatments for CIPN.
cause both acute and chronic peripheral neuropathy -chemotherapy induced peripheral neuropathy (CIPN). 4 During oncological treatment, the severity of the acute syndrome may require reducing the dose of chemotherapy or even stopping it, with potential impact on tumour control and survival. Chemotherapy-induced painful neuropathy (CIPN) is a major dose-limiting side-effect of several first-line chemotherapeutic agents. [5] [6] [7] [8] [9] [10] CIPN is a challenging and complex pain syndrome that we have no effective preventive and limited treatment options for currently. CIPN can have a major and prolonged impact on quality of life for patients. As oncological treatments have advanced, cancer survival has increased significantly, with many patients either being cured of cancer or living for many yr with cancer. Given the prevalence of the common cancers (e.g. breast, ovarian, colorectal) that these chemotherapeutics counteract, CIPN affects several million patients worldwide each yr. CIPN also places a significant economic burden on patients as a result of work-loss and the healthcare system because of its prevalence. 11 Effective collaboration between preclinical and clinical researchers is needed to translate improved understanding of the underlying mechanisms into development of effective preventive and treatment strategies. 12 This review aims to provide an overview of the clinical syndrome, its assessment, diagnosis and treatment, and how our improved understanding of underlying mechanisms contribute to this. While there are, multiple factors contributing to CIPN, we will focus particularly on areas where research findings from several different laboratories have highlighted potentially promising areas for development. These include the role of mitochondrial dysfunction, oxidative stress, immune cells and changes in ion channels in CIPN rodent models.
CIPN: the clinical syndrome
CIPN usually presents as a typical "glove and stocking" neuropathy. Patients describe a range of predominantly sensory symptoms including numbness, parathesia, ongoing/spontaneous pain, hypersensitivity to mechanical and/or cold stimuli in their hands and feet. In more severe cases, loss of vibration sense and joint position sense contribute to the impact on function. Autonomic and motor dysfunction may also occur.
Patients can have significant difficulty in essential daily functions including difficulty in fine finger movement such as buttoning clothing, and unsteady gait (numbness, loss of joint position sense); pain on walking (mechanical hypersensitivity); inability to remove items from a fridge, or exacerbation in cold weather (cold hypersensitivity). CIPN may present acutely, during chemotherapy, such as is commonly seen with platinum based compounds. 13 It may also occur after treatment has finished -a phenomenon known as "coasting" -where either mild neuropathy worsens, or new CIPN develops. This is challenging for oncologists, as there is no indication during chemotherapy to allow dose modification in order to reduce CIPN. 14 Pain and sensory abnormalities can persist for months or yr after the cessation of chemotherapy. 5 15 16 Therefore, patients may well be cancer-free, but suffering a debilitating neuropathy evoked by their cancer treatment. Peripheral neuropathy has been long associated with established drugs such as platinum agents (e.g. oxaliplatin), vinca alkaloids (e.g. vincristine), and taxanes (e.g. paclitaxel). However, newer, more targeted drugs, such as bortezomib, eribulin and ixabepilone 4, 17 are also associated with significant incidence of peripheral neuropathy. All of these chemotherapeutics have different mechanisms by which they evoke their anti-mitotic effects (e.g. perturbation of microtubule dynamics, DNA cross-linking, proteasome inhibition). Whether all these drugs evoke neurotoxicity by similar mechanisms remains to be determined.
Prevalence and risk factors for CIPN
The prevalence of CIPN varies between different agents, with reported rates varying from 19% to more than 85%. 18 While the agent and dose used is an important determining factor, there is no doubt that the lack of a gold standard agreed assessment tool impacts on reported rates of CIPN. 19 Accurate understanding of the epidemiology of CIPN, early identification and treatment of the clinical problem and evaluation of new treatments would all be improved by a standardized approach. The aim of the CI-PeriNomS Study Group was to assess reproducibility and validity of existing measures, and if necessary develop a simple and reproducible assessment for CIPN to try and meet this need. 31 A number of the tools available for assessing CIPN have been robustly assessed and show good reliability and validity (see Table 1 ). In patients with established CIPN QST abnormalities indicate deficits in A-beta fibre (altered touch detection to monofilaments, and altered bumps test), A-delta fibre (impaired sharpness detection) and C-fibre (pin prick) function. The importance of these findings is that classes of primary afferent fibres show differential impairments, indicating that the underlying mechanisms are particular to nerve fibre types as opposed to a nonspecific toxicity.
16 46 47 Changes in QST have been shown to be associated with alterations in epidermal nerve fibre density, occurring in a pattern that matches the distribution of symptoms, such that the lowest counts are in the painful area, but get progressively higher moving proximal where the symptoms change to numbness and then to no complaint. The decrease in Epidermal Nerve Fibre (ENF) density matches the QST data in these patients in that they had elevated pain and sharpness detection thresholds in the fingers and palm. 16 such local application of chemotherapy to understanding mechanisms of CIPN that are evoked by systemic administration is limited because of the high endoneurial concentration. In later studies, rodent models of paclitaxel-induced painful neuropathy were developed using systemic paclitaxel administered via i.v. or intraperitoneal routes for example 57 58 In fact, most of the dosing regimens (reviewed in 52 53 ) utilized to create rodent CIPN models involve intermittent systemic administration to mimic cycles of chemotherapy as opposed to daily dosing.
Typically, most models of CIPN involve the solo administration of a given chemotherapeutic in the absence of tumour load. However, there are reports using a rat model possessing an implanted subcutaneous tumour with combined paclitaxel and cisplatin treatment. 59 60 Animal health must be considered when using rodent models of CIPN for ethical reasons and practical feasibility. Pain-like behaviours cannot be accurately assessed if rodents are ill as a result of systemic toxicity and thus lethargic/unresponsive to hind paw stimulation. Although rodent models of CIPN with a tumour could be considered as more clinically relevant, the practical/ethical issues of this should not to be underestimated. In addition, as chemotherapy is often received after surgical removal of the tumour to eliminate possible micro-metastases, modelling CIPN through chemotherapy administration alone is a valid approach. For new preclinical investigations, the use of established intermittent dosing schedules to generate CIPN models is encouraged as much as possible. Wide adoption of the same dosing schedules across different laboratories would further understanding of causal mechanisms of CIPN and enhance reproducibility. CIPN models typically display sensory symptoms such as mechanical allodynia, mechanical hyperalgesia, cold allodynia, and in some reports, heat hyperalgesia. These symptoms are assessed by applying stimuli to hind paws of rodents and then measuring withdrawal responses to those stimuli. Mechanical stimuli used are typically von Frey filaments (calibrated nylon monofilaments when bent give a specific force) applied to the plantar surface of the hind paw or through paw pressure to the dorsum of the foot. Acetone application to the hind paw plantar surface provides a cooling stimulus, to measure cold allodynia. Heat hyperalgesia is measured through latency response to radiant heat application to the hind paw plantar surface.
Oxaliplatin-induced peripheral neuropathy is associated with an acute cold/mechanical hypersensitivity within h of administration and a chronic neuropathy. Both syndromes can be replicated in rats and mice at a range of systemic doses. 53 Studies with paclitaxel demonstrated that the cumulative dose administered affects both the integrity of peripheral nerves and the behavioural symptoms evoked. Systemic administration of lowdoses of paclitaxel (<10mg/kg cumulative dose) did not markedly affect neural microtubule structure or cause aggregation 61 as observed after epineural administration. [54] [55] [56] After low dose paclitaxel, neurodegeneration was not evident mid-axon or in the DRG, 61 however there was a loss of intraepidermal nerve fibres (IENFs). 62 63 Greater degrees of degeneration in peripheral nerves and the DRG were caused by larger cumulative doses of paclitaxel (<16mg/kg) in a dose-dependent manner. 57 64-66 The dose-dependent effects of paclitaxel administration have also been observed in patients, where the incidence and severity of neuropathic signs and symptoms increased relative to increasing cumulative doses of paclitaxel. 67 Paclitaxel-evoked behaviours in rodents are also dose-dependent. Mechanical and cold allodynia without motor deficit are observed at low doses. 58 68 69 In contrast, heat hypoalgesia and motor deficit is reported at high doses, which is likely indicative of significant neurodegeneration. 57 70-72 Collectively, these studies indicate that pain associated with CIPN is not necessarily a result of marked peripheral nerve degeneration.
Role of mitochondrial dysfunction in CIPN
Over the last decade, research has identified mitochondrial dysfunction has a significant contributory factor in CIPN. The first preclinical evidence identified swollen and vacuolated mitochondria in both myelinated axons and C-fibres in peripheral sensory nerves after systemic paclitaxel. 61 Paclitaxel-induced changes in neuronal mitochondria, correlated to the development and maintenance of paclitaxel-induced pain syndrome (i.e. present before and during paclitaxel-induced pain, but absent when the pain syndrome had resolved). 61 These low dose paclitaxel-induced mitochondrial changes in C-fibres and myelinated axons have since been confirmed by many groups. [73] [74] [75] [76] [77] [78] Paclitaxel increased the incidence of swollen/vacuolated mitochondria in dorsal root C-fibres and A-fibres 74 and the DRG, [78] [79] [80] but not in the ventral root or Schwann cells. 74 There is also evidence for mitochondrial dysfunction from the clinical literature. Two case reports show electron micrographs of sensory axons containing swollen, vacuolated mitochondria in sural nerve biopsies from patients with chemotherapy-induced neuropathy evoked by paclitaxel 81 and docetaxel. 82 Swollen/vacuolated mitochondria have also been observed in C-fibres and A-fibres of rat models of oxaliplatin-induced painful neuropathy 83 and bortezomib-induced painful neuropathy. 84 The presence of swollen mitochondria does not indicate the nature of mitochondrial dysfunction evoked. This can be determined through assays of mitochondrial function. Significant decreases in complex I-stimulated and complex II-stimulated respiration in sciatic nerves from paclitaxel-, oxaliplatin and bortezomib-treated rats were observed before, and during chemotherapy-induced pain behaviour. 84 85 Recent data discussed at NeupSIG 2017 demonstrates the maximal respiration and spare reserve capacity (the respiratory ability of the cell to overcome stress) were significantly decreased in DRG neurons from paclitaxel-treated 86 During paclitaxel-induced pain, these OXPHOS-driven respiratory deficits in DRG neurones resolved, yet DRG neurones become more glycolytic in their function and preferentially switch to glycolysis from OXPHOS. The switch to glycolysis may be an adaptive mechanism to produce less ROS and prevent apoptosis through the increased pentose phosphate pathway activity and elevated glutathione peroxidase levels. 87 These paclitaxel-evoked changes in bioenergetics are also associated with decreased ATP. Before and during paclitaxelinduced pain, less ATP was present in DRG neurones in situ, 86 yet deficits in ATP production in peripheral nerves are only observed during maximally stimulated conditions. 85 88 There was no change in the bioenergetic status of DRG neurones of paclitaxel-treated rats when the pain syndrome had resolved, 86 further indicating the contribution of these factors to the development and maintenance of paclitaxel-induced pain. Several studies have examined in vivo pharmacological modulation of the mitochondrial electron transport chain (ETC) in CIPN models. [89] [90] [91] Differential effects of specific complex inhibition have been observed (reviewed in 92 ) which may be explained by route of drug administration, inhibitor in question or time point examined post chemotherapy administration. For example, antimycin A (complex III inhibitor) significantly inhibited the development of paclitaxel-induced mechanical hypersensitivity when given before and during paclitaxel administration, but had no effect when given after paclitaxel administration. 91 Other alleviate CIPN. 77 78 93-95 99 Acetyl-L-carnitine (ALC) is involved in free fatty acid oxidation and acts as an antioxidant. Prophylactic ALC administration prevented the development of paclitaxelinduced mechanical hypersensitivity 99 paclitaxel-evoked increase in swollen/vacuolated mitochondria in C-fibres; 73 and paclitaxel-, oxaliplatin and bortezomib-evoked compromises in mitochondrial respiration in sciatic nerves. 84 85 Despite promising preclinical data [96] [97] [98] [99] and an open-label phase II trial of CIPN patients, 100 a placebo-controlled RCT reported prolonged ALC treatment was associated with more severe paclitaxel-evoked neurotoxicity in breast cancer patients. 101 TRO19622/Olesoxime, which directly binds to mitochondria (at the mPTP), attenuated chemotherapy-induced mechanical hypersensitivity and IENF loss, but had no effect on paclitaxel-induced spontaneous discharge in C-and A-fibres. 93 94 Inhibition of mitochondrial fission significantly attenuated oxaliplatin-induced mechanical hyperalgesia. 95 Pifithrin-l, an inhibitor of mitochondrial p53 accumulation, prevented development of paclitaxel-and cisplatin-induced mechanical hypersensitivity. 78 Pifithrin-l also prevented paclitaxel-evoked mitochondrial changes in sensory neurones and IENF loss with evidence of enhancement of paclitaxel's antitumour effects. 78 Similarly, minoxidil was recently shown to prevent paclitaxel-evoked nociceptive behaviour and mitochondrial changes in sensory neurones accompanied with augmentation of paclitaxel's anti-tumour action. 77 
Role of oxidative stress in CIPN
Mitochondria are a major source of reactive oxygen species (ROS) and increased ROS production can be a consequence of mitochondrial dysfunction. However, there are other cellular sources of ROS and reactive nitrogen species (RNS). Evidence for ROS involvement in neuropathic pain dates back to the 1990s 102 and ROS/RNS have multiple effects on neuronal excitability (reviewed in 103 ). The role of oxidative stress in CIPN has been examined in vivo using pharmacological reagents that scavenge ROS. PBN, a non-specific ROS scavenger, inhibited the development of paclitaxel-induced mechanical hypersensitivity; 104 105 reversed established paclitaxelinduced mechanical & cold hypersensitivities; 104 105 and bortezomib-induced mechanical hypersensitivity. 106 High doses of TEMPOL, a superoxide dismutase mimetic, inhibited the development and maintenance of paclitaxel-induced mechanical hypersensitivity, 105 107 but was ineffective on cold allodynia. 105 Another SOD mimetic, MnL4, inhibited oxaliplatin-induced mechanical and cold hypersensitivities. 108 Peroxynitrite decomposition catalysts have been shown to reverse established paclitaxel-induced mechanical hypersensitivity 109 and to also prevent the development of mechanical hypersensitivity induced by paclitaxel, oxaliplatin and bortezomib. 88 109 Novel mitochondria-targeted antio xidants have also been evaluated. SS-31 attenuated oxaliplatininduced cold & mechanical hypersensitivities. 110 MitoVitE attenuated the development of paclitaxel-induced mechanical hyper sensitivity.
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Other studies have measured ROS/RNS concentrations within the nociceptive system of CIPN models in vivo to understand the cellular basis/location of oxidative stress during CIPN. Increased RNS production was indicated in the spinal cord of paclitaxeltreated rats. 109 In addition, increased ROS and RNS concentrations were seen in lumbar DRG after chronic oxaliplatin treatment in mice. 110 Data discussed at NeupSIG 2017 showed how oxidative stress is linked to the development, maintenance and resolution of CIPN. ROS concentrations were elevated in superficial spinal neurones and non-peptidergic (IB4þ) DRG neurones, in vivo, before the onset of paclitaxel-induced pain behaviour, 87 suggesting ROS is an initiating factor. The preferential elevation of ROS in IB4þ neurones could suggest a direct mechanism by which TRPA1 channels, known neuronal ROS sensors and predominantly expressed on IB4þ DRG neurones, 112 contribute to paclitaxel-induced pain. 113 114 To understand how ROS was managed endogenously, we also examined the activity of different antioxidant enzymes in the DRG and peripheral sensory nerves during the time course of paclitaxel-induced painful neuropathy. Enhanced activity of mitochondrial and cellular endogenous antioxidant enzymes in the DRG and peripheral nerves was observed, however this was inadequate and delayed in its onset leading to excessive ROS in peripheral sensory axons. 87 Others have demonstrated an impaired mitochondrial antioxidant response after paclitaxel, oxaliplatin and bortezomib. 88 Collectively these in vivo preclinical studies suggest that mitochondrial ROS is causal to the development and maintenance of CIPN.
Role of immune cells in CIPN
In addition to effects on mitochondria and the generation of oxidative stress, chemotherapy agents also engage the innate immune system to induce peripheral neuropathy. A key mediator in this is the toll-like receptors (TLR). These are transmembrane proteins that normally function to detect various pathogens, TLR4 specialized to detect bacterial pathogens and TLR3 specialized to detect viral pathogens by example. TLR4 is also activated by several chemotherapeutics. 115 TLR4 and its immediate downstream signals are increased in the DRG of rats with paclitaxelinduced hyperalgesia; and this hyperalgesia can be prevented by co-treating animals with TLR4 antagonists during chemotherapy. 116 117 Similarly, mice with a genetic knockout of either TLR4 or TLR3 fail to develop hyperalgesia after treatment with cisplatin. 118 It appears that a key result of TLR4 activation by chemotherapeutics is to increase pro-inflammatory cytokine expression in the peripheral and central nervous systems. The C-C motif chemokine ligand 2 (CCL2, also called monocyte chemoattractant protein 1 or MCP1) and its receptor CCR2 are increased small DRG neurones that appear to be nociceptors and in spinal astrocytes in rats with paclitaxel related CIPN. 119 Gene knockdown or knockout of CCR2 or use of a chemical CCR2 antagonist reduced neuropathic pain in mice. 120 121 Macrophages are normally not found in large numbers in the DRG, yet the immediate result of the paclitaxel-induced increase in CCL2 in the DRG is a marked increase in these cells within the DRG within a few days of treatment. 122 These macrophages have a pro-inflammatory phenotype that results in increased concentrations of Interleukin-1 (IL-1) and Tumor necrosis factor alpha (TNFa) in the DRG. A number of studies have shown that pro-inflammatory cytokines such as these produce hyperalgesia to both thermal and mechanical stimuli. 123 124 This occurs by a number of mechanisms. IL-1 and TNFa act on both spinal and DRG neurones to lower their threshold of activation, a process termed sensitization, and to induce spontaneous discharges. [125] [126] [127] TNFa specifically also suppresses the signaling of spinal GABA neurones leading to central disinhibition of pain signaling. 128 IL-1 and TNFa, and IL-6 also increase the release of bradykinin, serotonin, and histamine that further augments pro-inflammatory processes. 129 130 Increased production and release of IL-1, TNFa and CCL2 is a shared effect after administration of several chemotherapeutics including paclitaxel, 131 cisplatin 132 and vincristine. 133 Importantly given that both neurones and glial cells express receptors for these cytokines and can also produce these after activation this mechanism has the potential to become self-sustaining. 134 Increased concentrations of IL-1, TNFa and CCL2 in the DRG and spinal cord produce alterations in Schwann cells along peripheral axons, satellite cells in the DRG, and astrocytes in the spinal cord that further contribute to chemotherapy related hyperalgesia. A constant observed after treatment with several different chemotherapy agents is that astrocytes show a downregulation in the expression of glutamate transporters. These are key to clearing synaptically released glutamate and dysfunction in this process leads to hyperexcitability of spinal neurones. As referenced above, the activation of Schwann cells leads to further release cytokines IL-1 and TNFa [135] [136] [137] (see more below), but also leads to the extirpation of these cells from peripheral axons, 64 resulting in reduced action potential propagation and longer term reduced protection and nourishment of nerve fibres. Satellite cells in the DRG react similarly to Schwann cells when exposed to chemotherapy agents 138 resulting in pro-apoptotic stress in DRG neurones. Satellite cells also increase their expression of gap junctions after chemotherapy treatment. Although the exact basis is unclear this appears to further promote pain signaling given that gap junction blockers produce an analgesic effect in CIPN mice. 139 An unusual aspect of glial response in the spinal cord is that astrocytes, but not microglia become activated in CIPN. [140] [141] [142] In many other types of neuropathic pain a primary role is assigned to microglia that does not appear to be involved in CIPN. Like in Schwann cells, inhibitors of gap junctions in astrocytes results in reduced hyperalgesia in CIPN, an a similar anti-hyperalgesic response is produced using the glial inhibitor minocycline. 143 144 Changes in ion channels in CIPN
The net result of the activation of innate immune responses in the DRG and spinal cord is the induction of hyperexcitability and ectopic spontaneous activity in both peripheral and spinal neurones. These, in turn are as a result of alterations in neuronal ionic homeostasis as revealed by ion channel microarray. 145 By example, given the primacy of Na þ ions in generating electrical activity in neurones, it is almost expected that alterations in voltage-gated sodium channels occur in CIPN. Recent work by our group that will be presented at NeuPSIG 2017 shows that the expression and function of the voltage-gated sodium channel Nav1.7 is markedly increased in DRG neurones after paclitaxel treatment and contributes directly to the development of ectopic spontaneous activity in nociceptors (Li and colleagues 2017, submitted). As well, prolonged opening in voltage-gated Naþ channels is produced by oxalate, a metabolite of oxaliplatin that results in lowered activation threshold and ectopic firing in DRG neurones. 146 147 Enhanced activity in sodium channels would appear to reflect the increased peripheral axonal excitability seen before symptom expression in patients. 148 149 Beyond the spinal cord and DRG, increased expression of voltage gated sodium channels is also found in forebrain regions after paclitaxel treatment. 150 A caveat to this latter observation is that forebrain changes in sodium channels would be secondary to alterations occurring elsewhere, given the poor penetrance of paclitaxel to the CNS. These preclinical observations are supported by clinical findings in that voltage-gated sodium channel blockers, such carbamazepine, that have found success in treating some, 151 but not all neuropathic pain patients.
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A second ion channel that is key in resulting neuronal excitability is that for potassium. Alterations in Kþ channel function have been noted at several levels of the neuraxis in CIPN. By example, Kþ channels are down-regulated in the cortex and in primary afferent neurones of rats with oxaliplatin CIPN; 153 154 and in the DRG of rats with paclitaxel-related CIPN. 145 In congruity with the observed changes in Naþ and Kþ channels just noted, others have reported an increased expression in hyperpolarization-activated channels (HCNs) that are permeable to both ions in CIPN. 155 Mathematical modelling of the consequences of the observed changes in Naþ and Kþ channels indicates that these account well for the observed hyper-excitability in nociceptors that occurs in oxaliplatin CIPN. 156 The therapeutic potential of targeting Kþ channels in CIPN is supported by the observation that the Kþ channel opener, retigabine, reduced signs of hyperalgesia in mice with cisplatin-related CIPN. 157 Voltage-gated calcium channels are key in regulating synaptic transmission and so not surprisingly also implicated in the hyper-excitability in CIPN. DRG neurones show increased levels of voltage-gated calcium channel mRNA after paclitaxel treatment in mice. 158 Antagonists to voltage-gated calcium channels including gabapentin and ethosuximide were both effective in reducing signs of hyperalgesia in rodents with paclitaxel-and vincristine-induced CIPN. 68 159 Consistent with these findings is that paclitaxel treatment was shown to alter calcium metabolism in primary afferent fibres 160 and treatment with minoxidil reversed this effect, while also ameliorating the behavioural signs of paclitaxel-related CIPN.
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A large group of non-selective cation channels specifically localized in nociceptors that are involved in CIPN symptoms is the transient receptor potential (TRP) channels. Specifically, the TRP vanilloid 1 (TRPV1) and the TRP ankyrin 1 (TRPA1) subgroups have been implicated in CIPN-related pain. TRPV1, commonly also known as the receptor for capsaicin (the active ingredient in hot chili peppers) is physiologically activated by protons, heat above 42 C, and endogenous lipids produced during inflammation (for review, see 161 ). The sensation produced by activation of TPV1 are exactly those that are experienced by CIPN patients, 16 48 in cutaneous nociceptors TRPV1 produces burning, 162 while in deep tissue nociceptors TRPV1 produces deep aching pain. 163 164 Paclitaxel activates and sensitizes the function of TRPV1 and TRPV1 antagonists produce analgesia in paclitaxel-related CIPN. 165 Similarly treatment with either bortezomib or cisplatin produced an increases in TRPV1 expression in DRG and spinal cord in mice. 166 167 Paclitaxel directly interacts with the TRPV1 channel to produce both and acute facilitation of signaling and also produces a long-term alteration of channel desensitization. The acute interaction has also been validated in human DRG neurones. 168 Parallel studies suggest that oxaliplatin also sensitizes the TRPV1 and that this effect is mediated by the G-protein coupled receptor G2A. 169 TRP ankyrin 1 (TRPA1) is often colocalized with TRPV1 and is activated by formalin, allyl isothiocyanate, and acrolein; and by temperatures below 17 C. 170 Given that activation of TRPA1 is activated by noxious cold stimuli in animals, 171 it has been suggested that this channel may mediate the acute hypersensitivity to cold observed in patients after oxaliplatin treatment. Preclinical studies using oxaliplatin appear to support this view 172 173 and appear to also be generalizable to paclitaxel-induced cold hyperalgesia. 113 Preclinical studies have further detailed that chronic symptoms of CIPN may be mediated by chemotherapy-induced activation of proteinase-activated receptors (PARs) that activate phospholipase C, protein kinase A and protein kinase C epsilon that then sensitize TRPA1 and TRPV1 and TRPV4 channels, respectively.
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Further support for a role of TRPA1 in CIPN is that receptor deficient mice were shown to be resistant to both oxaliplatin-and bortezomib-related CIPN. 174 
